Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

INTRODUCTION: The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Main Authors: Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Wolden, Michael Lyng, Haldrup, Steffen, Schultes, Bernd
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2019
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824376/
https://ncbi.nlm.nih.gov/pubmed/30879256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00916-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares